Clinical Research

Investigators have announced discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood. Umbilical cord blood contains adult stem…

Merck is discontinuing the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (L-BLP25) as a monotherapy in Stage III non-small cell lung cancer…

The U.S. Food and Drug Administration has approved Keytruda (pembrolizumab), a new immunotherapy drug to treat advanced melanoma after it was tested on more than 600 patients who had melanoma…

In an oral presentation at the 2014 European Society of Cardiology (ESC) Congress in Barcelona, Dr. Jan Johansson, senior vice president of medical affairs at Resverlogix, disclosed that patients…

Positive results from its final preclinical toxicology study of SYN-004 have led Synthetic Biologics to get ready for clinical trials of the anti-infective, second-generation product candidate for…

In 2014, there will be an estimated 22,240 new cases of ovarian cancer in the United States and over 40,000 new cases in the European Union. Ovarian cancer is one of the most lethal gynecologic…

Enrollment in a randomized Phase II clinical trial of Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS) has…

A newly developed antifungal named isavuconazole is as effective as voriconazole against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data.…

A simple solution to a persistent problem. Credit: Ashok A. Kumar By Ashok A. Kumar, Harvard University Every year, 300,000 children are born with sickle-cell disease, primarily in Africa and India…

 Reperfusion injury prevention isn't possible just yet. The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing…